All In Biotech

Drug Trial Radar · NCT05582499

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N)

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 716 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

716

Planned (sponsor's estimate)

Start

Nov 1, 2022

Primary completion

Dec 31, 2027

Study completion Sep 2029

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for neoadjuvant chemotherapy and by the update of basic translational research in the center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs, verified the effectiveness of new targeted drugs in neoadjuvant therapy.

Conditions

  • Breast Neoplasm
  • Breast Cancer
  • Breast Tumors
  • Triple-Negative Breast Cancer (TNBC)
  • HER2-positive Breast Cancer
  • HER2-negative Breast Cancer
  • Hormone Receptor Positive Tumor
  • Hormone Receptor Negative Tumor
  • Early-stage Breast Cancer
  • Locally Advanced Breast Cancer

Interventions

  • DalpiciclibDrug

    an oral cyclin-dependent kinases (CDK) 4/6 inhibitor

  • PyrotinibDrug

    an irreversible dual pan-erbb receptor tyrosine kinase receptor tyrosine kinase (ERBB) inhibitor

  • SHR-A1811Drug

    an anti-HER2 antibody-drug conjugate (ADC)

  • SHR-1316Drug

    an anti-programmed death ligand 1 (PD-L1) antibody

  • CamrelizumabDrug

    an anti-programmed death-1 (PD1) antibody

  • SHR-A1921Drug

    Trophoblast cell-surface antigen 2 (TROP2) ADC

  • PertuzumabDrug

    Pertuzumab

  • TrastuzumabDrug

    Trastuzumab

  • GoserelinDrug

    goserelin

  • LetrozoleDrug

    letrozole

  • Nab paclitaxelDrug

    Albumin paclitaxel

  • CarboplatinDrug

    Carboplatin

  • EpirubicinDrug

    Epirubicin

  • CyclophosphamideDrug

    Cyclophosphamide

  • FluzoparibDrug

    an original poly adenosine diphosphate-ribose polymerase (PARP) inhibitor

  • ApatinibDrug

    tyrosine kinase inhibitors

  • FamitinibDrug

    tyrosine kinase inhibitors

  • HB1801Drug

    Albumin docetaxel

  • LEMDrug

    liposome-entrapped mitoxantrone

  • TQB2102Drug

    an anti-HER2 ADC

  • BenmelstobartDrug

    an anti-PDL1 antibody

  • AnlotinibDrug

    an tyrosine kinase inhibitor

  • TQB2868Drug

    anti-PD-1/TGF-βRII

  • IvonescimabDrug

    an anti-PD-1/VEGF bispecific antibody

  • JS207Drug

    an anti-PD-1/VEGF bispecific antibody

  • JSKN003Drug

    an anti-HER2 ADC

  • HRS-4508Drug

    an HER2 inhibitor

  • SHR-4602Drug

    an anti-HER2 ADC

  • paclitaxelDrug

    paclitaxel

  • HRS-6209Drug

    an oral cyclin-dependent kinases 4 (CDK4) inhibitor

  • 9MW2821Drug

    a Nectin-4 antibody-drug conjugate (ADC)

  • IBI354Drug

    an anti-HER2 ADC

  • Stereotactic Body Radiation Therapy (SBRT)Radiation

    Stereotactic Body Radiation Therapy (SBRT) is performed within 5 calendar days prior to the initiation of drug therapy. SBRT is delivered to the primary tumor in 3 fractions of 8 Gy each (total 24 Gy) over 3-5 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological complete response rate (pCR)Time frame: through study completion, up to 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center Shanghai, China, 200032

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.